Organogenesis Holdings Inc.
$2.52
▼
-3.03%
2026-04-21 08:40:01
organogenesis.com
NCM: ORGO
Explore Organogenesis Holdings Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$324.17 M
Current Price
$2.52
52W High / Low
$7.08 / $2.21
Stock P/E
8.75
Book Value
$2.36
Dividend Yield
—
ROCE
11.21%
ROE
9.04%
Face Value
—
EPS
$0.15
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
854
Beta
1.48
Debt / Equity
18.93
Current Ratio
3.62
Quick Ratio
3.32
Forward P/E
8.21
Price / Sales
0.54
Enterprise Value
$426.17 M
EV / EBITDA
5.68
EV / Revenue
0.76
Rating
Strong Buy
Target Price
$8
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Some data points may be missing or delayed because the source is not an official exchange feed.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Akanda Corp. | $3.42 | — | $1.89 M | — | -102.48% | -60.86% | $209.03 / $2.29 | $22.67 |
| 2. | Journey Medical Corporation | $5.19 | — | $147.31 M | — | -14.3% | -44.03% | $9.55 / $4.31 | $1.17 |
| 3. | Incannex Healthcare Inc. | $3.84 | — | $51 M | — | — | -1.3% | $49.8 / $2.4 | $6.13 |
| 4. | InMed Pharmaceuticals Inc. | $0.72 | — | $2.4 M | — | -57.63% | -97.2% | $7.98 / $0.57 | $3.42 |
| 5. | cbdMD, Inc. | $0.81 | — | $7.12 M | 0% | -29.93% | -43.36% | $2.56 / $0.47 | $0.89 |
| 6. | Universe Pharmaceuticals INC | $3.32 | — | $1.9 M | — | -5.19% | -7.23% | $11 / $2 | $99.64 |
| 7. | Harrow, Inc. | $40.5 | — | $1.51 B | — | 10.06% | -8.47% | $54.85 / $21.12 | $1.41 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 225.07 M | 150.49 M | 100.78 M | 86.69 M | 126.66 M | — |
| Operating Profit | 65.23 M | 21.65 M | -10.83 M | -20.18 M | 10.22 M | — |
| Net Profit | 43.7 M | 21.57 M | -9.39 M | -18.84 M | 7.67 M | — |
| EPS in Rs | 0.34 | 0.17 | -0.07 | -0.15 | 0.06 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 563.03 M | 482.04 M | 433.14 M | 450.89 M |
| Operating Profit | 55.87 M | 21.52 M | 12.53 M | 22.3 M |
| Net Profit | 37.03 M | 0.86 M | 4.95 M | 15.53 M |
| EPS in Rs | 0.29 | 0.01 | 0.04 | 0.12 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 598.73 M | 497.89 M | 460.02 M | 449.36 M |
| Total Liabilities | 164.81 M | 112.57 M | 181.36 M | 183.69 M |
| Equity | 433.92 M | 385.32 M | 278.66 M | 265.67 M |
| Current Assets | 362.19 M | 285.94 M | 225.04 M | 222.61 M |
| Current Liabilities | 100.12 M | 77.48 M | 80.51 M | 75.02 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.31 M | 14.21 M | 30.92 M | 24.86 M |
| Investing CF | -14.15 M | -10.03 M | -24.36 M | -33.9 M |
| Financing CF | -17.36 M | 27.64 M | -5.5 M | -2.2 M |
| Free CF | -24.46 M | 4.18 M | 6.55 M | -9.04 M |
| Capex | -14.15 M | -10.03 M | -24.36 M | -33.9 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 11.29% | -3.94% | — | — |
| Earnings Growth % | -82.59% | -68.16% | — | — |
| Profit Margin % | 0.18% | 1.14% | 3.44% | — |
| Operating Margin % | 4.46% | 2.89% | 4.95% | — |
| Gross Margin % | 75.99% | 75.42% | 76.71% | — |
| EBITDA Margin % | 5% | 8.32% | 8.94% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.